Good evening :)
Place Order
Add to Watchlist

Indoco Remedies Ltd

INDOCO

Indoco Remedies Ltd

INDOCO
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,212 cr, stock is ranked 945
Moderate RiskStock is 2.24x as volatile as Nifty
334.651.44% (-4.90)
334.651.44% (-4.90)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,212 cr, stock is ranked 945
Moderate RiskStock is 2.24x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,212 cr, stock is ranked 945
Moderate RiskStock is 2.24x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
41.882.89—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.916.640.47%

Forecast & Ratings

Detailed Forecast 
75%
Analysts have suggested that investors can buy this stock

from 4 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Indoco Remedies Limited is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.64%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.44% to 0.49%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,009.681,078.731,046.63974.601,109.021,244.651,543.081,670.951,846.871,852.48
Raw Materialssubtract361.13362.83344.53306.93338.48366.23483.09514.74600.671,599.57
Power & Fuel Costsubtract21.7223.1226.6228.4934.7536.8942.7850.6156.00
Employee Costsubtract181.87216.67220.91231.66256.51274.02296.28322.58361.93
Selling & Administrative Expensessubtract216.81255.89246.31241.21287.26257.82292.67339.43414.96
Operating & Other expensessubtract56.1859.7968.6483.5166.3882.3098.59155.15147.62
Depreciation/Amortizationsubtract60.6663.2867.7171.5770.8273.1378.9670.6191.8799.51
Interest & Other Itemssubtract12.396.2123.5120.5426.2522.2614.1425.0338.0244.54
Taxes & Other Itemssubtract16.9913.877.23-6.414.4638.9581.7750.5537.3332.16
EPS8.898.364.47-0.312.6210.1016.8015.4410.688.32
DPS1.601.601.000.300.301.502.252.25—2.25
Payout ratio0.180.190.22—0.110.150.130.150.000.27

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Indoco Remedies Ltd32.622.89—
Sun Pharmaceutical Industries Ltd48.196.880.70%
Cipla Ltd32.685.020.78%
Torrent Pharmaceuticals Ltd68.9816.660.83%

Price Comparison

Compare INDOCO with any stock or ETF
Compare INDOCO with any stock or ETF
INDOCO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding58.75%17.04%1.62%1.47%21.10%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun1.54%1.57%1.59%1.69%1.91%1.47%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Indoco Remedies Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Small Cap Fund - Growth - Direct Plan

Growth
4.7246%0.59%0.00%77/109 (-10)
Nippon India Small Cap Fund - Growth - Direct Plan

Growth
3.0880%0.16%0.00%148/231 (-43)
DSP Healthcare Fund - Growth - Direct Plan

Growth
2.5147%2.75%0.01%15/33 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2024

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Sep 19, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹2.25

Dividend/Share

₹2.25

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateSep 14, 2022

Special
Special | Div/Share: ₹0.75

Dividend/Share

₹0.75

Ex DateEx Date

Sep 14, 2022

Cash Dividend

Ex DateEx DateSep 14, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Sep 14, 2022

Cash Dividend

Ex DateEx DateSep 17, 2021

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Sep 17, 2021

News & Opinions
Corporate
Indoco Remedies receives USFDA approval for Cetirizine Hydrochloride Tablets

Indoco Remedies (Indoco) announced the receipt of final approval from the USFDA for Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets USP, 10 mg (OTC), a generic equivalent of the Reference Listed Drug, Zyrtec Allergy Tablets, 10 mg of Johnson & Johnson Consumer Inc. Cetirizine Hydrochloride Tablets USP, 10 mg will be manufactured by Indoco, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India. Cetirizine is used for relief of symptoms of hay fever and other allergic conditions.Powered by Capital Market - Live

3 hours agoCapital Market - Live
Corporate
Indoco Remedies AGM scheduled

Indoco Remedies announced that the Annual General Meeting (AGM) of the company will be held on 26 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Indoco Remedies fixes record date for final dividend

Indoco Remedies has fixed 19 September 2024 as record date for determining entitlement of members to final dividend for the financial year ended 31 March 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live

Stock that will see action today: July 29, 2024

2 months agoThe Hindu Businessline

Indoco Remedies consolidated net profit declines 89.26% in the June 2024 quarter

2 months agoBusiness Standard
Earnings
Indoco Remedies consolidated net profit declines 89.26% in the June 2024 quarter

Net profit of Indoco Remedies declined 89.26% to Rs 2.62 crore in the quarter ended June 2024 as against Rs 24.39 crore during the previous quarter ended June 2023. Sales rose 1.79% to Rs 424.29 crore in the quarter ended June 2024 as against Rs 416.81 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales424.29416.81 2 OPM %11.2614.68 - PBDT34.4953.79 -36 PBT6.9733.91 -79 NP2.6224.39 -89 Powered by Capital Market - Live

2 months agoCapital Market - Live

Stock Alert: Reliance Industries, Cyient DLM, Zensar Tech, Suzlon Energy, Federal Bank, Gensol Engineering

2 months agoBusiness Standard

Indoco Remedies - U.S. To Drive Growth: Nirmal Bang

3 months agoBloomberg Quint

USFDA Approves Indoco Remedies’ Generic Diabetes Drug

3 months agoBloomberg Quint

Indoco Remedies - Resolution Of Facilities A Key Monitorable: Nirmal Bang

1 year agoBloomberg Quint